Poor Survival in Glioblastoma Patients is Associated with Early Signs of Immunosenescence in the CD4 T-cell Compartment After Surgery
Overview
Authors
Affiliations
Patients with glioblastoma multiforme (GBM) are immunosuppressed and have a broad range of immunological defects in both innate and adaptive immune responses. GBMs are frequently infected with human cytomegalovirus (HCMV), a virus capable of causing immunosuppression. In 42 HCMV-positive GBM patients in a clinical trial (VIGAS), we investigated T-cell phenotypes in the blood and assessed their relation to survival. Blood was collected before and 3, 12, and 24 weeks after surgery, and the frequency of T-cell subsets was compared with that in 26 age-matched healthy controls. GBM patients had lower levels of CD3 cells than the controls, but had significantly higher levels of CD4CD28 T cells before and 3 and 12 weeks after surgery and increased levels of CD4CD57 and CD4CD57CD28 T cells at all-time points. These T-cell subsets were associated with both immunosenescence and HCMV infection. GBM patients also had higher levels of γδ T cells at all-times after surgery and lower levels of CD4CD25 cells before and 3 weeks after surgery than healthy controls. Overall survival was significantly shorter in patients with higher levels of CD4CD28 T cells ( 0.025), CD4CD57 T ( 0.025) cells, and CD4CD28CD57CD28 T cells ( 0.0004) at 3 weeks after surgery. Our findings indicate that signs of immunosenescence in the CD4 compartment are associated with poor prognosis in patients with HCMV-positive GBMs and may reflect the HCMV activity in their tumors.
Rosichini M, Del Baldo G, De Luca C, Benini F, Genah S, Vinci M NPJ Precis Oncol. 2024; 8(1):269.
PMID: 39567679 PMC: 11579487. DOI: 10.1038/s41698-024-00755-y.
Unravelling the mosaic: Epigenetic diversity in glioblastoma.
Lucchini S, Constantinou M, Marino S Mol Oncol. 2024; 18(12):2871-2889.
PMID: 39148319 PMC: 11619803. DOI: 10.1002/1878-0261.13706.
Senescent T Cells in Age-Related Diseases.
Yu P, Zhou M, Liu Y, Du J Aging Dis. 2024; .
PMID: 38502582 PMC: 11745454. DOI: 10.14336/AD.2024.0219.
Losurdo A, Di Muzio A, Cianciotti B, Dipasquale A, Persico P, Barigazzi C Cancers (Basel). 2024; 16(3).
PMID: 38339353 PMC: 10854506. DOI: 10.3390/cancers16030603.
Dusoswa S, Verhoeff J, van Asten S, Lubbers J, van den Braber M, Peters S Front Immunol. 2024; 15:1343484.
PMID: 38318180 PMC: 10839779. DOI: 10.3389/fimmu.2024.1343484.